# Mercia EIS Fund | a regional early-stage technology fund with a strong track record and attractive tax advantages

## The fund

Mercia EIS offers investors access to a fund of approximately 12 pioneering technology-driven businesses that Mercia has identified as high growth opportunities and is actively advising and scaling up.

Beginning as a venture capital firm in 1982, Mercia is now one of the UK's most active and respected early-stage technology investors, investing over  $\mathfrak{L}100\text{m}$  each year across over 550 new and existing portfolio companies.

Mercia began investing EIS Funds in 2013 and also manages the Northern VCTs.


# **Key features**

- Minimum investment: £25,000
- Target portfolio size: Approximately 12 companies
- Target performance: 3x invested capital (including income tax relief and loss relief)
- Holding period: 5-7 years
- Closing dates: We always have an EIS Fund open, with funds closing at the end of March, June, September and December of each year
- An online investor centre where you can view your investment at any time

## Where we invest

Mercia is proud to invest in regions across the UK underserved by other venture capital investment firms.

The UK regions offer exciting deals with businesses in various sectors that are reasonably priced and have relatively modest capital requirements. These lower valuations often mean better returns on your investment.



# **Fund performance**

Mercia EIS Funds' performance is among the strongest in the industry and is on target for 3x invested capital over five to seven years (including tax reliefs).

- EIS funds before April 2015 average 3.3x
- EIS funds before April 2018 average 2.5x
- EIS funds before April 2021 average 2.1x

All the above valuations include tax reliefs and are as of September 2023.

## **Recent exits**

- Oxgene sold in March 2021, a return of up to 20x
- GENBA Digital sold in May 2021, a return of up to 8x (including earn out)
- Snappy Shopper sold in July 2021, a circa 8x return
- nDreams was sold in March 2022, a circa 7.8x return for EIS investors
- C7 Health was sold in June 2022, a circa 14.1x return for EIS investors

# **Example portfolio companies**


#### Axis Spine Technology

Axis develops next-generation spinal implants to provide surgeons with the technology to improve the success of spinal surgery and help patients in chronic pain.

The technology has attracted significant commercial interest and will soon be demonstrating its clinical benefits in the US's £7.0billion spinal implant market, with several top US spine surgeons ready to start using the device.

#### Locate Bio

Locate has three powerful orthobiologic platform technologies from two leading academic research groups, from which we have created several late-stage products addressing the repair and regeneration of both bone and cartilage.



#### MIP Diagnostics

A biotech company that develops molecularly imprinted polymers (MIPs) that can be used to replace antibodies in diagnostic tests and other applications.



## The Mercia EIS Investor Centre

Many of our services are available via the Investor Centre, where you can view your investment at any time, including:

- An investment dashboard
- Digital tax certificates
- Loss relief letters
- Contract notes

### How to invest

An online application may be completed by your adviser and sent to your email address for you to diaitally sian

Once received, we will contact you to confirm once the account has been opened, at which point you may send the subscription to us via bank transfer.



#### Download the IM



# **Risk warnings**

Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. EIS investments are restricted to high net worth or sophisticated individuals, or those advised by a qualified financial adviser, per FCA rules. Evidence of qualification is required with your application. Tax treatment depends on the individual circumstances of each client and may be subject to change in future. Read the full risk warnings in the Fund documentation before applying. Past performance does not predict future results. These investments are illiquid and may lack a readily available market for selling. Investments in non-Sterling currencies may be affected by exchange rate changes. Mercia Fund Management Limited, a subsidiary of Mercia Asset Management PLC, is the EIS fund manager and authorised and regulated by the FCA (FRN: 524856).

Take 2 minutes

